SLC22A11
MOLECULAR TARGETsolute carrier family 22 member 11
SLC22A11 (solute carrier family 22 member 11) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SLC22A11
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as | 0.69 | 1 |
| 2 | Cefazolin | 0.69 | 1 |
| 3 | Cefoperazone Semisynthetic broad-spectrum cephalosporin with | 0.69 | 1 |
| 4 | cefotaxime | 0.69 | 1 |
| 5 | Ceftriaxone | 0.69 | 1 |
| 6 | Cephaloridine | 0.69 | 1 |
| 7 | Dehydroepiandrosterone Sulfate | 0.69 | 1 |
| 8 | Dinoprost | 0.69 | 1 |
| 9 | Dinoprostone | 0.69 | 1 |
About SLC22A11 as a Drug Target
SLC22A11 (solute carrier family 22 member 11) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented SLC22A11 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SLC22A11 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.